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Abstract: Myelodysplastic syndrome (MDS) is a spectrum of diseases, characterized by debilitating
cytopenias and a propensity of developing acute myeloid leukemia. Comprehensive sequencing
efforts have revealed a range of mutations characteristic, but not specific, of MDS. Epidemiologically,
autoimmune diseases are common in patients with MDS, fueling hypotheses of common etiological
mechanisms. Both innate and adaptive immune pathways are overly active in the hematopoietic niche
of MDS. Although supportive care, growth factors, and hypomethylating agents are the mainstay
of MDS treatment, some patients—especially younger low-risk patients with HLA-DR15 tissue
type—demonstrate impressive response rates after immunosuppressive therapy. This is in contrast to
higher-risk MDS patients, where several immune activating treatments, such as immune checkpoint
inhibitors, are in the pipeline. Thus, the dual role of immune mechanisms in MDS is challenging,
and rigorous translational studies are needed to establish the value of immune manipulation as a
treatment of MDS.
Keywords: myelodysplastic syndrome; autoimmunity; adaptive immunity; innate
immunity; Pancytopenia
1. Introduction
Myelodysplastic syndrome (MDS) encompasses a range of diseases, characterized by inefficient
hematopoiesis leading to debilitating cytopenias [1]. The spectrum of MDS ranges from indolent
disease without the need for blood product transfusion to borderline acute myeloid leukemia (AML),
and may arise de novo, secondary to other myeloid disorders, or after exposure to cytotoxic therapy
(therapy-related MDS). Even in the novel 2016 World Health Organization classification of MDS,
diagnostics are almost purely based on cytological and histological examination of peripheral blood
and bone marrow, offering limited characterization of the biology of the disease. The only exception
are del(5q) and SF3B1, which contribute to the diagnostic criteria of MDS, with isolated del(5q)
and MDS with ring sideroblasts, respectively [2]. Recent years have uncovered a large spectrum of
point mutations in MDS, the majority being in splicing factors and epigenetic regulators [3–5]. Such
mutations reflect clinical outcomes [6], relate to clinical phenotypes [7], and will likely be incorporated
into future prognostic scoring systems. However, no somatic mutations have proven pathognomonic
of MDS, as these mutations can be detected in patients with other myeloid malignancies and in people
without dysplastic bone marrow [8,9]. Individuals with these mutations may be healthy and have
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normal blood counts or idiopathic cytopenia of undetermined significance (ICUS). A fraction of these
will develop MDS over time [9], but the factors determining progression have yet to be identified.
A paramount feature of low-risk MDS is increased apoptosis of hematopoietic precursors [10,11].
Both genetic and epigenetic alterations, as well as immune mechanisms, may contribute to this
phenomenon [12]. Immune dysregulation has been intensively studied and has repeatedly been
reported as the cause of apoptosis in MDS [12]. Furthermore, many patients seem to benefit from
immunosuppressive therapy [13]. Epidemiological studies of large cohorts have established a link
between autoimmune disease and MDS [14–16]. In this review, we explore the link between immune
dysregulation and MDS, and its role in current and potential future treatment of the disease.
2. Association with Autoimmune Disease
Myelodysplasia has long been associated with autoimmune diseases on an anecdotal basis. More
recently, large cohort studies have confirmed such a link [14–18]. Database studies have shown an
increased odds ratio (OR) of between 1.5 to 3.5 for developing MDS in patients with prior autoimmune
disease [14,16,18,19]. However, these epidemiological studies lack data on treatment given for the
autoimmune disease. Some patient groups have probably received immunosuppressive drugs, such as
methotrexate, azathioprine, or cyclophosphamide, which may induce therapy-related MDS [20–22].
Looking at the autoimmune diseases individually in a Swedish study, some diseases had a particularly
high OR of 23.9 for idiopathic thrombocytopenic purpura (ITP), 7.9 for myasthenia gravis, and 5.4
for giant cell arteritis [16]. One study found hypothyroidism in 12% of patients (<4% in the general
population), but it was not verified if hypothyroidism was of autoimmune origin (Hashimoto’s
thyroiditis) [17]. Another study from the General Practice Research Database in the United Kingdom
failed to replicate this association, but found a strong relation to systemic lupus erythematosus and
inflammatory bowel disease [18]. Psoriasis and rheumatoid arthritis are other diseases overrepresented
in MDS [17]. One could suspect some surveillance bias (i.e., surveillance of autoimmune disease leads
to faster MDS diagnosis), but adjustment for number of visits to the General Practitioner did not alter
the increased risk found in the United Kingdom study [18]. Taken together, these studies suggest that
autoimmunity could underlie both hematological and systemic autoimmune morbidity. On the other
hand, idiopathic cytopenia of undetermined significance (ICUS) that may precede MDS [8,9] may
also be associated with immune dysregulation or even autoimmune manifestations. One might also
speculate that patients with presumed idiopathic thrombocytopenic purpura (ITP) and subsequent
MDS may have had clonal disease all along. Studies from our own lab show that some MDS patients
have a preceding clonal thrombocytopenia for up to eight years before developing MDS, and a subset of
patients with ITP have detectable mutations in epigenetic regulators without progressing to MDS [23].
It is conceivable that progression from ITP to MDS can be driven by a compromised immune system.
In general, patients with MDS and concurrent autoimmune disease fail to demonstrate consistent
characteristic demographic, clinical, or paraclinical features [15,17]. Prognostically, one study found
prior autoimmune disease to be a beneficial predictor of longer survival and less progression to
acute myeloid leukemia (AML) [17], although another smaller study did not detect any significant
difference [15].
3. Immune Dysregulation in MDS
3.1. T-Cell Mediated Bone Marrow Suppression
Apoptosis is the hallmark of low-risk MDS [11] and may be attributed to dysfunctional T-cell
response and innate immune activation [12,24]. In MDS, naïve T-cells (CD3+) exhibit shorter telomere
length and have significantly less proliferative potential [25]. More than 90% of MDS-patients harbor
oligoclonal T-cells [26], and most of these are derived from the malignant MDS-clone [27]. In vitro
studies have demonstrated that autologous T-cells inhibit growth of both malignant and non-malignant
hematopoiesis [28–30]. This may be mediated through CD8+ T-cells targeting MHC-class I molecules
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on hematopoietic precursors (Figure 1). Although clonal repertoires have been described through flow
cytometry and PCR of the T-cell receptor (TCR), these methods cannot themselves identify the epitopes
targeted on hematopoietic stem cells in MDS. A recent study was able to identify Wilms tumor 1 protein
as a potential epitope for autologous T-cells in trisomy 8 MDS [31]. Another study demonstrated a
T-cell reactivity against cancer-testes antigens in MDS, a response that was potentiated by treatment
with the hypomethylating agent (HMA) azacitidine [32]. This autologous T-cell response is a part of
tumor surveillance. Many of the IST regimes tested in MDS affect T-cell function, which could hinder
tumor surveillance and induce disease progression. Contrary to this notion, clinical trials actually
demonstrated similar or less risk of progression to AML after immunosuppressive therapy [33]. An
explanation may be that MDS tumor cells already have escaped tumor surveillance through a variety
of mechanisms ranging from dysfunctional T-cells and cytokine expression to altered stroma in the
hematopoietic niche [34–37]. Recently, suppressors of activated T-lymphocytes, such as programmed
death-1 (PD-1), its ligand programmed death ligand 1 (PD-L1), and T lymphocyte-associated antigen
4 (CTLA4), have attracted a great deal of attention in oncology [38]. In MDS, these seem to play an
active role in escape of tumor surveillance and resistance to therapy [34,39,40].
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Figure 1. Potential echanism of bone marrow suppression by T-cells. CD8+ T-cells are activated
by major histocompatibility complex (MHC)-class I complex on malignant MDS stem cells, which
leads to T-cell expansion which in turn suppress hematopoiesis. T-cells secrete proinflammatory
cytokines such as tumor necrosis factor (TNF)-α and interferon gamma (IFN)-γ into the bone arro
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T-cell mediated suppression of hematopoietic stem cells has been recognized as an attribute of
aplastic anemia [41]; distinction of this entity from hypoplastic MDS can be difficult. Recent advances
in the mutational mapping have demonstrated that almost half of the patients with aplastic anemia
harbor mutations characteristic of MDS, indicating that at least some of these patients may indeed
have MDS associated with T-cell activation [42].
3.2. Cytokines
The expression of at least thirty cytokines has been found to be skewed in patients with
DS [12,43,44] and some patterns relate to the clinical subtype and outcome [12]. These cytokines
may be expressed by MDS tumor cells, stromal cells or they may reflect systemic inflammatory activity.
Tumor necrosis factor alpha (TNF-α) is well-studied in MDS; it is overexpressed in cultured cells from
patients with MDS [45] and elevated in bone marrow and peripheral blood plasma [44,46,47]. The
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level of TNF-α appears to be inversely related to hemoglobin and survival [47]. Stromal bone marrow
cells are one source of TNF-α [43], but systemic inflammatory activity may also be a significant source.
Furthermore, interferon-γ (IFN-γ) is secreted locally by activated T-cells [48] as well as by stromal
macrophages [43]. In vitro, TNF-α and INF-γ greatly enhance the expression of the Fas receptor (FasR)
on hematopoietic precursors [49], which renders them susceptible to Fas ligand (FasL) mediated
apoptosis. Tumor necrosis factor–related apoptosis-inducing ligand (TRAIL) and its agonistic receptors
show significant overactivity in MDS leading to apoptosis of precursors with some preference for the
malignant clone [50].
3.3. Innate Immunity Activity
Innate immunity is composed of humoral and cellular immune mechanisms, which mostly rely
on generic recognition of microbial markers through pattern recognition receptors. In mammals,
this recognition most often relies on toll-like receptors (TLRs) [51]. The TLR signaling pathway
results in activation of the nuclear factor k-light-chain-enhancer of activated B cells (NF-kB)
and mitogen-activated protein kinase (MAPK) pathways, which in turn induce transcription of
pro-inflammatory cytokines [51]. In many cases of MDS, TLR signaling pathways are severely
overactive due to overexpression of activators such as MYD88, TIRAP, IRAK1/4, TRAF and
downregulation of inhibitory factors, such as miR145 and miR146a [12,52]. MicroRNAs (miRNAs)
are small nucleotides used for post-translational regulation of Mrna [53] and their role in regulating
hematopoiesis is well described [54,55]. MiR145 and miR146a are both deleted in 5q- MDS [52]. MiR145
and targets TIRAP, whereas miRNA146b works downstream of that by inhibiting TRAF6 [52].
3.4. Mesenchymal Stromal Cells (MSC)
Hematopoiesis occur in the hematopoietic niche in which stems cells are nurtured by supporting
MSC [56]. MSC are primitive and self-renewing cells capable of differentiating into mesodermal cell
types such as adipocytes, chondrocytes, and osteocytes [56]. Increasingly, MSC are recognized as
pivotal in maintaining normal hematopoiesis as well as in fueling the pathogenesis of the malignant
MDS clone [57]. This is illustrated by the inability of human MDS stem cells to engraft in murine
xenograft models. Engraftment is substantially improved by injecting MSC along with hematopoietic
MDS stem cells into the bone marrow of xenograft mice [37]. Additionally, altered gene and miRNA
expression profiles of have been reported in MSC of patients with MDS [58]. One gene differentially
expressed in MSC of MDS patients, Dicer1, has been selectively deleted in MSC in a murine model, and
this alteration alone was shown to induce MDS and AML [59]. Notably, in the context of this review,
MSC exert substantial immunosuppressive activity by paracrine and cell-to-cell interaction [60]. T-cells
are arrested in G1-phase and their cytokine secretion is diminished [61–63]. One effector of this T-cell
inhibition is indoleamine 2,3-dioxygenase (IDO), which is secreted by MSC [64]. As described below,
clinical trials are investigating the potential of IDO in treatment of several malignancies including
MDS. MSC themselves secrete a broad range of other cytokines capable of modulating numerous
leukocyte subsets [64]. Importantly, this immunomodulation differs between low- and high-risk MDS
patients with MSC from high-risk patients inducing more apoptosis and immunosuppression while
providing less hematopoietic support [60].
4. Immune Manipulation as Treatment of MDS
As both innate and adaptive immune reactivity seem to participate in the development of low-risk
MDS, immunosuppressive therapy would be a rational treatment in this diseases entity. However,
in high-grade MDS, escape of immune surveillance by the adaptive immune system may be crucial
for MDS blast survival [12,39,65], thus providing yet another target for therapy. Several trials have
examined the potential effect of immune manipulation in low- and high-risk MDS, which will be
briefly reviewed in the following.
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4.1. Which Low-Risk MDS Patients Are Subceptible to Immunosuppressive Therapy
As low-risk MDS represents a range of disease entities, the susceptibility to immunosuppressive
therapy differs widely. Age is strongly and inversely related to immunosuppressive therapy
response [33]. Other factors associated with response to immunosuppressive therapy are HLA-DR15
tissue type, low international prognostic scoring system (IPSS) score, hypocellular bone marrow,
and trisomy 8 [31,33,66,67]. Presence of a PNH-clone would intuitively indicate autoimmunity and
thus prediction of response to immunosuppressive therapy, but this only seems the case in aplastic
anemia [42] and not in MDS [33]. A recent phase II trial in patients with MDS has provided a
multivariate response model incorporating younger age, short disease duration, high percent CD8+
terminal memory cells, and high percent CD4+ Ki67+ as markers of response to anti-thymocyte
globulin (ATG) [68].
4.2. Cyclosporine, Anti-Thymocyte Globulin, and Mycophenolate Mofetil
Cyclosporine specifically targets T-cell activation through binding to the cytosolic protein
cyclophilin, as well as blockage of the JNK and p38 pathways [69]. Early small trials of cyclosporine
monotherapy in low-risk MDS provided impressive hematological response rates of 33%–82%
for anemia, whereas thrombocytopenia and neutropenia proved more treatment-resistant [70–72].
Anti-Thymocyte Globulin (ATG) binds to lymphocytes [73] and briefly depletes T-lymphocytes in
circulation and lymph nodes. Furthermore, regulatory T-cells are upregulated and antigen presentation
inhibited after ATG [74,75]. The overall result is diminished adaptive immunity [72]. Horse and rabbit
ATG have been used for more than 30 years to treat aplastic anemia [76] with horse ATG as the most
effective option in this disease [77]. Although considered a separate entity, hypoplastic MDS shares
many features with aplastic anemia [66], and recent sequencing studies have revealed considerable
overlap in somatic mutations among the two disorders [42]. This prompted studies with ATG for
hypoplastic MDS and then for normo- and hyperplastic MDS [30,78]. Response rates vary between
0%–100% and greatly depend on the selection of patients [72,79]. Combination therapy of cyclosporine
and ATG has not been proven superior to monotherapy, although some patients may be dependent on
cyclosporine maintenance after ATG [79,80]. Mycophenolate Mofetil (MMF) is an immunosuppressant
prodrug. It is metabolized in the liver to mycophenolic acid, which hinders purine synthesis in
lymphocytes [81]. MMF is approved for use after organ transplantations. One small study has
investigated its use in low-risk MDS patients, most of whom had failed EPO treatment [82]. Treatment
was well tolerated and did not require hospitalization. Five of ten patients responded to treatment
with three demonstrating major responses.
4.3. Alemtuzumab
Alemtuzumab is a monoclonal antibody directed against CD52, which is primarily located
on the surface of mature lymphocytes. Treatment with alemtuzumab depletes lymphocytes thus
crippling adaptive immunity. In MDS, alemtuzumab has shown impressive response rates of 72%
in IPSS intermediate-1 and intermediate-2 patients deemed likely to respond to immunosuppressive
therapy [83].
4.4. Novel Immune Pathway Inhibitors
Improved understanding of immune mechanisms implicated in MDS offers new targets for
treatment. The overactivity of TLR pathways in MDS provides a rationale for using inhibitory
drugs. Many compounds have been tested preclinically. In vitro data suggest impressive single agent
activity of p38 MAPK inhibitors [84], prompting a phase I trial of the p38 MAPK inhibitor ARRY614
(NCT01496495/NCT00113893). The TLR2 inhibitor OPN-305 has passed a phase I trial in healthy
subjects and is currently being tested in a phase I/II trial in patients with MDS (NCT02363491).
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4.5. Epigenetic Modulation and Induction of Adaptive Immunity in Higher Risk MDS
While it is well established that accumulation of genetic and epigenetic abnormalities in the
malignant blasts may aggravate MDS, it is becoming increasingly evident that evasion of adaptive
immune surveillance is an important feature in higher risk MDS. One of the main mechanisms might
be the adaptation of immune checkpoint molecules by the malignant cells, thereby suppressing the
specific immunological anti-tumor responses [34,39]. Accordingly, a rational strategy may be to block
immune checkpoints in higher-risk MDS [85].
Currently, two clinical trials are investigating the use of programmed death ligand 1 (PD-L1)
inhibitors in MDS. Pembrolizumab, a PD-L1 inhibitor approved for use in melanoma, is undergoing a
phase 1 trial as a single agent against MDS and lymphomas (NCT02508870). Another PD-L1 blocking
antibody, Atezolizumab, is being tested with and without the HMA azacitidine in an ongoing phase
1 trial (NCT02508870).
Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) is expressed on helper T-cells and provides
an inhibitory signal to other T-lymphocytes thus acting as a checkpoint [86]. The CTLA-4 inhibitor
Ipilimumab, approved in melanoma, is in phase 1 trial in relapsed/refractory MDS before or after
stem cell transplantation (NCT01757639, NCT01822509).
The tryptophan degrading enzyme IDO is expressed by a range of tumor cells [87]. This
exhausts L-Trp from the tumor microenvironment, which effectively dampens T-cell proliferation and
activity [88]. Results from a recent phase II trial of the IDO1 inhibitor INCB024360 demonstrated stable
disease in 12 of 15 patients during the follow-up period, while the remaining three patients progressed
(NCT01822691).
The HMAs that are clinically approved for the treatment of higher-risk MDS, have the potential to
modulate and induce immune responses against the malignant cells in different ways [89–92]. Recently,
it was shown that the mechanism of the increased immune signaling could be demethylation and
upregulation of endogenous retroviruses (ERVs) [93,94]. Upregulated ERVs may form double stranded
RNA that activate the viral defense pathway and contribute to decreased proliferation and apoptosis of
the target cells; a phenomenon called viral mimicry [95]. This mechanism may play an important role
in the anti-tumor activity of the HMAs and may sensitize malignant MDS cells to immune checkpoint
blockade or other immunotherapies [96]. Additionally, upregulation of tumor associated antigens such
as cancer-testis antigens, has been shown to promote T cell reactivity following HMA therapy [32,97].
Therefore, it will be of high interest to evaluate the efficacy of the combination treatment of HMAs and
immune checkpoint inhibition in higher-risk MDS patients.
5. Discussion
The diagnosis of MDS still mostly relies on careful examination of blood and bone marrow
morphology. Karyotyping is obligatory as cytogenetic status is used in current prognostic scoring
systems [98,99]. Targeted gene screening panels are becoming commercially available and will
assist in classification in the next World Health Organization classification guideline as well as
in future prognostic scores. Although autoimmunity has been recognized in low-risk MDS for
almost two decades [71,78], the mechanisms underlying immune activation in MDS and their
therapeutic implications are still sparsely understood. Initial studies have focused on adaptive
immunity inducing apoptosis in hematopoietic precursors in low-risk MDS [100]. Despite an extensive
search, only cancer-testes antigens and WT1 antigen have been recognized as T-cell epitopes in
MDS [31,32]. Therapies, such as ATG, cyclosporine, and alemtuzumab, work primarily by suppressing
adaptive immunity and have shown substantial therapeutic potential for selected patients with
low-risk MDS [83]. Despite impressive response rates in selected subgroups, the potential of
immunosuppressive therapy is still not widely appreciated clinically. In part, this may be explained
by the lack of effective tools to reliably identify patients with MDS that are likely to respond to
immunosuppressive therapy. Currently, one would expect a younger patient with short duration of
disease, HLA-DR15 tissue type, and low IPSS-R score to respond to immunosuppressive therapy [68,83].
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Precision may be improved by adding flow cytometric characterization of T-cell populations [68].
Thus far, effective immunosuppressive therapy in MDS has mostly been built on trial and error with
known methodologies working in other autoimmune diseases. Identifying novel markers and targets
of autoimmunity in MDS will require deeper understanding of its underlying biological mechanisms.
Recently, adaptive immunity has attracted much attention in high-risk MDS. As with
melanoma [38], harnessing tumor surveillance by pharmacologically releasing cytotoxic lymphocytes
from their bonds may prove instrumental in providing lasting responses in higher risk MDS patients.
However, given the role of autoimmunity in low-risk MDS, careful monitoring of adverse effects
of immune check point inhibitors in higher risk MDS will be crucial, as these drugs are associated
with increased risk of autoimmunity. Increasingly, evidence of innate immunity dysregulation in
the hematopoietic niche of MDS is also mounting. This is paving the way for novel inhibitors of
innate immune pathways and may widen the use of immune manipulation in MDS. Such targets will
hopefully provide effective and less toxic treatment options for an often fragile patient population.
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Abbreviations
AML Acute myeloid leukemia
ATG Anti-thymocyte globulin
ERVs Endogenous retroviruses
FasL Fas ligand
FasR Fas receptor
HMA Hypomethylating agent ICUS Idiopathic cytopenia of undetermined significance
IDO Indoleamine 2,3-dioxygenase
IFN-γ Interferon-γ IPSS International Prognostic Scoring System
IPSS-R Revised International Prognostic Scoring System
ITP Idiopathic thrombocytopenic purpura
MAPK Mitogen-activated protein kinase
MDS Myelodysplastic syndrome MHC Major histocompatibility complex MMF Mycophenolate Mofetil
MSC Mesenchymal stromal cells
NF-κB Nuclear factor k-light-chain-enhancer of activated B cells
NSAIDs Non-steroidal anti-inflammatory drugs
RA Refactory anemia
RCMD Refractory anemia with multilineage dysplasia
TCR T-cell receptor
TNF-α Tumor necrosis factor α
TRAIL Tumor necrosis factor–related apoptosis-inducing ligand
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